Rothlein R, Jaeger J R
Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT 06877, USA.
Ciba Found Symp. 1995;189:200-8; discussion 208-11. doi: 10.1002/9780470514719.ch14.
A mouse monoclonal antibody to intercellular adhesion molecule 1 (ICAM-1) has been evaluated in multiple animal models of inflammation as well as in the clinic. Anti-ICAM-1 has been found to protect against allograft rejection and ischaemia/reperfusion injury in non-human primates and rabbits. In open-label phase I-II studies, anti-ICAM-1 appears to have prolonged kidney allograft survival when used as induction therapy in conjunction with traditional triple immunosuppressive therapy. Anti-ICAM-1 has shown beneficial effects in the treatment of rheumatoid arthritis when given for five days. Most patients receiving anti-ICAM-1 made antibodies to the mouse immunoglobulin.
一种针对细胞间黏附分子1（ICAM-1）的小鼠单克隆抗体已在多种炎症动物模型以及临床中进行了评估。已发现抗ICAM-1可预防非人类灵长类动物和兔子的同种异体移植排斥反应和缺血/再灌注损伤。在开放标签的I-II期研究中，抗ICAM-1与传统三联免疫抑制疗法联合用作诱导疗法时，似乎可延长肾移植的存活时间。抗ICAM-1连续给药五天时，已显示出对类风湿性关节炎的治疗有益。大多数接受抗ICAM-1治疗的患者产生了针对小鼠免疫球蛋白的抗体。
